NS3 and its cofactor NS4A make up the complex known as HCV NS3-4A serine protease. It is crucial for processing viral polyproteins, RNA replication, and virion formation and contains serine protease and NTPase/RNA helicase activities.
The HCV NS3/4A protease efficiently cleaves and inactivates two important signaling molecules in the sensory pathways that react to HCV pathogen-associated molecular patterns (PAMPs) to induce interferons (IFNs), i.e., mitochondrial antiviral signaling protein (MAVS) and Toll-IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF). HCV infection is associated with chronic liver disease, including hepatic steatosis, fibrosis, cirrhosis, and hepatocellular carcinoma. The NS3-4A serine protease of HCV has been one of the most attractive targets for developing specific antiviral agents against HCV.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V3157 | Boceprevir (EBP-520; SCH-503034) | 394730-60-0 | Boceprevir (previously known as EBP 520; SCH 503034; trade name: Victrelis) is a novel, orally bioavailable, selective, direct acting inhibitor ofhepatitis C virus (HCV) protease with Ki value of 14 nM for NS3 in an enzyme assay andEC90of 350 nM in cell-based replicon assay. |
|
V9749 | Faldaprevir | 801283-95-4 | Faldaprevir (BI201335; BI-201335) is a novel and potent potent NS3/NS4A protease inhibitor with the potential to be used inthe treatment of HCV infection. |
|
V3159 | Grazoprevir | 1350514-68-9 | Grazoprevir (formerly MK-5172;MK5172; trade name: Zepatier) is a 2nd generation and selective inhibitor of theHepatitis C Virus NS3/4A Proteaseapproved by FDA in 2016 for the treatment of hepatitis C (used in combination with elbasvir, an NS5A replication complex inhibitor). |
|
V22361 | HZ-1157 | 1009734-33-1 | HZ-1157 can inhibit HCV (hepatitis C virus) NS3/4A protease with IC50 of 1.0 μmol/L. |
|
V80973 | NS5A-IN-1 | NS5A-IN-1 is a precursor of the hepatitis C virus NS5A inhibitor Pibrentasvir (ABT-530). | |
|
V73168 | NS5A-IN-2 | 2764786-74-3 | NS5A-IN-2 (Compound 33) is a potent NS5A inhibitor. |
|
V73169 | NS5A-IN-3 | 2764786-56-1 | NS5A-IN-3 (Compound 15) is a potent NS5A inhibitor. |
|
V3915 | VOXILAPREVIR | 1535212-07-7 | Voxilaprevir (formerly GS-9857; GS9857;trade name:Vosevi) is a hepatitis C virus nonstructural protein (HCV NS) 3/4A protease inhibitor developed by Gilead and approved in 2017 as an anti-HCV drug for use in combination with sofosbuvir and velpatasvir. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
